Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients

Dustin D. Spencer, Judith Jacobi, JoEtta M. Juenke, James Fleck, Michael B. Kays

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Study Objectives. To characterize the steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients requiring seizure prophylaxis after a neurologic injury and to determine which dosing regimens achieve serum concentrations within the recommended therapeutic range of 6-20 μg/ml. Design. Prospective, open-label, steady-state pharmacokinetic study. Setting. Neurocritical care unit in a tertiary care medical center. Patients. Twelve adults (five men, seven women) admitted to the neurocritical care unit who required prophylactic anticonvulsant therapy after subarachnoid hemorrhage, subdural hematoma, or traumatic brain injury. Intervention. Patients received an intravenous infusion of levetiracetam 500 mg over 15 minutes every 12 hours. Measurements and Main Results. Serial blood samples were collected from all patients after a minimum of four doses of therapy. Serum levetiracetam concentrations were determined by ultraperformance liquid chromatography with tandem mass spectrometry detection, and pharmacokinetic data were analyzed by compartmental and noncompartmental methods. Monte Carlo simulations were performed for multiple levetiracetam dosing regimens to determine the probability of achieving a target trough concentration of 6 μg/ml or greater, 20 μg/ml or greater, and 6-20 μg/ml. The mean ± SD levetiracetam maximum serum concentration was 28.0 ± 8.0 μg/ml, minimum serum concentration 3.1 ± 1.8 μg/ml, half-life 5.2 ± 1.2 hours, systemic clearance 5.6 ± 1.8 L/hour, and volume of distribution at steady state 36.8 ± 6.3 L. Increasing the doses of levetiracetam increased the probability of achieving a target trough concentration of 6 μg/ml or greater but also increased the probability of achieving trough concentrations greater than 20 μg/ml. Levetiracetam doses of 1000 mg every 8 hours and 1500-2000 mg every 12 hours provided the highest probability of achieving a target trough concentration between 6 and 20 μg/ml. Conclusion. Compared with previously published results in healthy volunteers and adults in status epilepticus, levetiracetam systemic clearance was faster and the terminal elimination half-life was shorter in neurocritical care patients. Higher doses or more frequent dosing may be needed to achieve target trough concentrations of 6-20 μg/ml.

Original languageEnglish
Pages (from-to)934-941
Number of pages8
JournalPharmacotherapy
Volume31
Issue number10
DOIs
StatePublished - Oct 2011

Fingerprint

etiracetam
Patient Care
Pharmacokinetics
Serum
Half-Life
Nervous System Trauma
Subdural Hematoma
Status Epilepticus
Subarachnoid Hemorrhage
Tandem Mass Spectrometry
Intravenous Infusions
Tertiary Care Centers

Keywords

  • Levetiracetam
  • Neurocritical care
  • Pharmacokinetics
  • Seizure prophylaxis

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients. / Spencer, Dustin D.; Jacobi, Judith; Juenke, JoEtta M.; Fleck, James; Kays, Michael B.

In: Pharmacotherapy, Vol. 31, No. 10, 10.2011, p. 934-941.

Research output: Contribution to journalArticle

Spencer, Dustin D. ; Jacobi, Judith ; Juenke, JoEtta M. ; Fleck, James ; Kays, Michael B. / Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients. In: Pharmacotherapy. 2011 ; Vol. 31, No. 10. pp. 934-941.
@article{e70d6c2e0813495186b7b28eb470e252,
title = "Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients",
abstract = "Study Objectives. To characterize the steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients requiring seizure prophylaxis after a neurologic injury and to determine which dosing regimens achieve serum concentrations within the recommended therapeutic range of 6-20 μg/ml. Design. Prospective, open-label, steady-state pharmacokinetic study. Setting. Neurocritical care unit in a tertiary care medical center. Patients. Twelve adults (five men, seven women) admitted to the neurocritical care unit who required prophylactic anticonvulsant therapy after subarachnoid hemorrhage, subdural hematoma, or traumatic brain injury. Intervention. Patients received an intravenous infusion of levetiracetam 500 mg over 15 minutes every 12 hours. Measurements and Main Results. Serial blood samples were collected from all patients after a minimum of four doses of therapy. Serum levetiracetam concentrations were determined by ultraperformance liquid chromatography with tandem mass spectrometry detection, and pharmacokinetic data were analyzed by compartmental and noncompartmental methods. Monte Carlo simulations were performed for multiple levetiracetam dosing regimens to determine the probability of achieving a target trough concentration of 6 μg/ml or greater, 20 μg/ml or greater, and 6-20 μg/ml. The mean ± SD levetiracetam maximum serum concentration was 28.0 ± 8.0 μg/ml, minimum serum concentration 3.1 ± 1.8 μg/ml, half-life 5.2 ± 1.2 hours, systemic clearance 5.6 ± 1.8 L/hour, and volume of distribution at steady state 36.8 ± 6.3 L. Increasing the doses of levetiracetam increased the probability of achieving a target trough concentration of 6 μg/ml or greater but also increased the probability of achieving trough concentrations greater than 20 μg/ml. Levetiracetam doses of 1000 mg every 8 hours and 1500-2000 mg every 12 hours provided the highest probability of achieving a target trough concentration between 6 and 20 μg/ml. Conclusion. Compared with previously published results in healthy volunteers and adults in status epilepticus, levetiracetam systemic clearance was faster and the terminal elimination half-life was shorter in neurocritical care patients. Higher doses or more frequent dosing may be needed to achieve target trough concentrations of 6-20 μg/ml.",
keywords = "Levetiracetam, Neurocritical care, Pharmacokinetics, Seizure prophylaxis",
author = "Spencer, {Dustin D.} and Judith Jacobi and Juenke, {JoEtta M.} and James Fleck and Kays, {Michael B.}",
year = "2011",
month = "10",
doi = "10.1592/phco.31.10.934",
language = "English",
volume = "31",
pages = "934--941",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "10",

}

TY - JOUR

T1 - Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients

AU - Spencer, Dustin D.

AU - Jacobi, Judith

AU - Juenke, JoEtta M.

AU - Fleck, James

AU - Kays, Michael B.

PY - 2011/10

Y1 - 2011/10

N2 - Study Objectives. To characterize the steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients requiring seizure prophylaxis after a neurologic injury and to determine which dosing regimens achieve serum concentrations within the recommended therapeutic range of 6-20 μg/ml. Design. Prospective, open-label, steady-state pharmacokinetic study. Setting. Neurocritical care unit in a tertiary care medical center. Patients. Twelve adults (five men, seven women) admitted to the neurocritical care unit who required prophylactic anticonvulsant therapy after subarachnoid hemorrhage, subdural hematoma, or traumatic brain injury. Intervention. Patients received an intravenous infusion of levetiracetam 500 mg over 15 minutes every 12 hours. Measurements and Main Results. Serial blood samples were collected from all patients after a minimum of four doses of therapy. Serum levetiracetam concentrations were determined by ultraperformance liquid chromatography with tandem mass spectrometry detection, and pharmacokinetic data were analyzed by compartmental and noncompartmental methods. Monte Carlo simulations were performed for multiple levetiracetam dosing regimens to determine the probability of achieving a target trough concentration of 6 μg/ml or greater, 20 μg/ml or greater, and 6-20 μg/ml. The mean ± SD levetiracetam maximum serum concentration was 28.0 ± 8.0 μg/ml, minimum serum concentration 3.1 ± 1.8 μg/ml, half-life 5.2 ± 1.2 hours, systemic clearance 5.6 ± 1.8 L/hour, and volume of distribution at steady state 36.8 ± 6.3 L. Increasing the doses of levetiracetam increased the probability of achieving a target trough concentration of 6 μg/ml or greater but also increased the probability of achieving trough concentrations greater than 20 μg/ml. Levetiracetam doses of 1000 mg every 8 hours and 1500-2000 mg every 12 hours provided the highest probability of achieving a target trough concentration between 6 and 20 μg/ml. Conclusion. Compared with previously published results in healthy volunteers and adults in status epilepticus, levetiracetam systemic clearance was faster and the terminal elimination half-life was shorter in neurocritical care patients. Higher doses or more frequent dosing may be needed to achieve target trough concentrations of 6-20 μg/ml.

AB - Study Objectives. To characterize the steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients requiring seizure prophylaxis after a neurologic injury and to determine which dosing regimens achieve serum concentrations within the recommended therapeutic range of 6-20 μg/ml. Design. Prospective, open-label, steady-state pharmacokinetic study. Setting. Neurocritical care unit in a tertiary care medical center. Patients. Twelve adults (five men, seven women) admitted to the neurocritical care unit who required prophylactic anticonvulsant therapy after subarachnoid hemorrhage, subdural hematoma, or traumatic brain injury. Intervention. Patients received an intravenous infusion of levetiracetam 500 mg over 15 minutes every 12 hours. Measurements and Main Results. Serial blood samples were collected from all patients after a minimum of four doses of therapy. Serum levetiracetam concentrations were determined by ultraperformance liquid chromatography with tandem mass spectrometry detection, and pharmacokinetic data were analyzed by compartmental and noncompartmental methods. Monte Carlo simulations were performed for multiple levetiracetam dosing regimens to determine the probability of achieving a target trough concentration of 6 μg/ml or greater, 20 μg/ml or greater, and 6-20 μg/ml. The mean ± SD levetiracetam maximum serum concentration was 28.0 ± 8.0 μg/ml, minimum serum concentration 3.1 ± 1.8 μg/ml, half-life 5.2 ± 1.2 hours, systemic clearance 5.6 ± 1.8 L/hour, and volume of distribution at steady state 36.8 ± 6.3 L. Increasing the doses of levetiracetam increased the probability of achieving a target trough concentration of 6 μg/ml or greater but also increased the probability of achieving trough concentrations greater than 20 μg/ml. Levetiracetam doses of 1000 mg every 8 hours and 1500-2000 mg every 12 hours provided the highest probability of achieving a target trough concentration between 6 and 20 μg/ml. Conclusion. Compared with previously published results in healthy volunteers and adults in status epilepticus, levetiracetam systemic clearance was faster and the terminal elimination half-life was shorter in neurocritical care patients. Higher doses or more frequent dosing may be needed to achieve target trough concentrations of 6-20 μg/ml.

KW - Levetiracetam

KW - Neurocritical care

KW - Pharmacokinetics

KW - Seizure prophylaxis

UR - http://www.scopus.com/inward/record.url?scp=80053303384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053303384&partnerID=8YFLogxK

U2 - 10.1592/phco.31.10.934

DO - 10.1592/phco.31.10.934

M3 - Article

C2 - 21950640

AN - SCOPUS:80053303384

VL - 31

SP - 934

EP - 941

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 10

ER -